

## Enhanced CD95 and interleukin 18 signalling accompany T cell receptor V $\beta$ 21.3+ activation in multi-inflammatory syndrome in children

Zhang, Zhenguang; Kean, Iain R. L.; Dratva, Lisa M.; Clark, John A.; Syrimi, Eleni; Khan, Naeem; Daubney, Esther; White, Deborah; O'Neill, Luran; Chisholm, Catherine; Payne, Caroline; Benkenstein, Sarah; Kupiec, Klaudia; Galassini, Rachel; Wright, Victoria; Winmill, Helen; Robbins, Ceri; Brown, Katherine; Ramnarayan, Padmanabhan; Scholefield, Barnaby

DOI:

[10.1038/s41467-024-48699-y](https://doi.org/10.1038/s41467-024-48699-y)

License:

Creative Commons: Attribution (CC BY)

### Document Version

Publisher's PDF, also known as Version of record

### Citation for published version (Harvard):

Zhang, Z, Kean, IRL, Dratva, LM, Clark, JA, Syrimi, E, Khan, N, Daubney, E, White, D, O'Neill, L, Chisholm, C, Payne, C, Benkenstein, S, Kupiec, K, Galassini, R, Wright, V, Winmill, H, Robbins, C, Brown, K, Ramnarayan, P, Scholefield, B, Peters, M, Klein, N, Montgomery, H, Meyer, KB, Teichmann, SA, Bryant, C, Taylor, G & Pathan, N 2024, 'Enhanced CD95 and interleukin 18 signalling accompany T cell receptor V $\beta$ 21.3+ activation in multi-inflammatory syndrome in children', *Nature Communications*, vol. 15, no. 1, 4227. <https://doi.org/10.1038/s41467-024-48699-y>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## Description of Additional Supplementary Files

**Supplementary Data 1:** Additional clinical and demographic information of children included in this study. (a) Clinical symptoms, SARS-Cov-2 status and treatment information for the MIS-C patients in the whole blood functional assay study. (b) Demographics of paediatric fever controls (n=16) used in the whole blood functional assay study. (c) Demographics of LRTI Cohort (n=22) used in the 48-plex cytokine array study. (d) Demographics of general infection (non-covid) cohort (n=14) used in mass cytometry study.